| Drug Name |
4r,6r-dorzolamide |
| Drug ID |
BADD_D00006 |
| Description |
Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380] |
| Indications and Usage |
Dorzolamide is indicated for the management of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.[L11377] It can also be used in combination with [timolol] for the same indication in patients who are insufficiently responsive to ophthalmic beta-blockers.[L11380]
Its pre-operative use was also investigated to prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy.[A190183] |
| Marketing Status |
approved |
| ATC Code |
S01EC03 |
| DrugBank ID |
DB00869
|
| KEGG ID |
D07871; D00653
|
| MeSH ID |
C062765
|
| PubChem ID |
92087
|
| TTD Drug ID |
D05UYW
|
| NDC Product Code |
70377-081; 14445-404 |
| UNII |
55O5C6I73D
|
| Synonyms |
dorzolamide | 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | dorzolamide, (trans)-isomer | Dorzolamide Chibret | MK 507 | MK-507 | Trusopt | dorzolamide hydrochloride | L 671152 | L-671,152 |
